Calidi Biotherapeutics, Inc. Payments of Financing Costs
Calidi Biotherapeutics, Inc. (CLDI) reported Payments of Financing Costs of $289.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. payments of financing costs for the quarter ending 2026-06-30 was $118.00K, a 47.50% increase year-over-year.
- Calidi Biotherapeutics, Inc. payments of financing costs for the quarter ending 2026-03-31 was $171.00K, a 43.19% decline year-over-year.
- Calidi Biotherapeutics, Inc. payments of financing costs for the quarter ending 2025-12-31 was $121.00K, a 75.90% decline year-over-year.
- Calidi Biotherapeutics, Inc. payments of financing costs for the quarter ending 2025-09-30 was $344.00K, a 26.94% increase year-over-year.
- Calidi Biotherapeutics, Inc. payments of financing costs for fiscal 2025 was $846.00K, a 45.56% decline from fiscal 2024.
- Calidi Biotherapeutics, Inc. payments of financing costs for fiscal 2024 was $1.55M, a 27.92% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. payments of financing costs for fiscal 2023 was $2.16M, a 3617.24% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. payments of financing costs for fiscal 2022 was $58.00K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $118.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $289.00K 10-Q · filed 2026-08-13 | $410.00K derived: sum of 3 quarters · filed 2026-08-13 | $754.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $171.00K 10-Q · filed 2026-05-14 | $292.00K derived: sum of 2 quarters · filed 2026-05-14 | $636.00K derived: sum of 3 quarters · filed 2026-05-14 | $716.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $465.00K derived: sum of 2 quarters · filed 2026-03-27 | $545.00K derived: sum of 3 quarters · filed 2026-08-13 | $846.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $344.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $424.00K derived: sum of 2 quarters · filed 2026-08-13 | $725.00K 10-Q · filed 2025-11-13 | $1.23M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $381.00K 10-Q · filed 2026-08-13 | $883.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $301.00K 10-Q · filed 2026-05-14 | $803.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.07M derived: sum of 3 quarters · filed 2026-05-14 | $1.69M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $502.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $773.00K derived: sum of 2 quarters · filed 2026-03-27 | $1.39M derived: sum of 3 quarters · filed 2026-03-27 | $1.55M 10-K · filed 2026-03-27 |
| 2024-09-30 | $271.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $890.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.05M 10-Q · filed 2025-11-13 | $1.71M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $619.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $781.00K 10-Q · filed 2025-08-08 | $1.44M derived: sum of 3 quarters · filed 2025-08-08 | $1.95M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $162.00K 10-Q · filed 2025-05-14 | $822.00K derived: sum of 2 quarters · filed 2025-05-14 | $1.33M derived: sum of 3 quarters · filed 2025-05-14 | $2.25M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $660.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.17M derived: sum of 2 quarters · filed 2025-03-31 | $2.08M derived: sum of 3 quarters · filed 2025-03-31 | $2.16M 10-K · filed 2025-03-31 |
| 2023-09-30 | $507.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.43M derived: sum of 2 quarters · filed 2024-11-12 | $1.50M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $918.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $989.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $71.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $58.00K 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |